Supplmentary Figures S1- S2 and Tables S1- S7 from Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain

Supplementary Figure S1 describes the pre-existing antibody responses to tumor antigens in patients with surgically resected HER2+ breast cancer. Supplementary Figure S2 compares the proportion of either the metastatic or adjuvant patients that respond to therapy with increased antibody responses. Table S1 shows the demographic information for the patients in this study. Table S2 compares the levels of antibodies to tumor antigens and TT in metastatic patients and healthy controls. Table S3 compares the mean pre- and post-treatment antibody levels to all of the tumor antigens and TT in the patients with metastatic disease. Table S4 describes correlations of the antibody responses to the type of chemotherapy received in the metastatic patients. Table S5 shows the results of a cox univariate analysis correlating PFS and antibody responses. Table S6 shows the results of a cox univariate analysis correlating OS and antibody responses. Table S7 compares the mean pre- and post-treatment antibody levels to all of the tumor antigens and TT in patients with surgically-resected disease.